11 February 2016
Amsterdam, NL – The Journal of Alzheimer’s Disease (JAD) is proud to announce the launch of the Alzheimer’s Funding Analyzer (AFA) on the JAD website. It is a free service that is part of a new suite of online features that have been designed to serve the needs of the Alzheimer disease (AD) research community.
AFA presents in-depth data on 115 funders from 42 countries including all of the European Union, Australia, Canada, Ireland, Qatar, the United Kingdom, and the United States.
“It is increasingly difficult to keep up with all of the organizations currently funding AD research around the globe,” explained JAD’s Editor-in-Chief George Perry, PhD, Dean and Professor of Biology, The University of Texas at San Antonio. “For this reason, JAD has developed the AFA to make this information systematically available. It will enable researchers to identify research activities years before they appear in the published literature.”
Working with development partner ÜberResearch, a solutions and services company focused on the specific needs of science funders, AFA includes all funding related to AD drawn from ÜberResearch’s extensive grant database of more than $900 billion of funded research, representing more than 1.9 million projects from 150 funders like the National Institutes of Health and the National Science Foundation in the U.S. and the Wellcome Trust and U.K. Research Councils in the U.K.
The AFA allows users to easily locate funding related to AD and analyze funding streams and trends. Further, it facilitates a better understanding of research organizations’ funding portfolios and the funding patterns of specific funders, both of which are critical when developing grant applications. For example, users can conduct line-of-investigation queries (e.g., tau, ApoE4, vaccine) to look for funding trends and to see which investigators in which countries have been the most successful in obtaining funding in a given area of AD research. New funding information will be added to the AFA on an ongoing basis.
”We invite all AD researchers to register at www.j-alz.com/funding for this valuable service, which we are pleased to make available at no charge,” added Dr. Perry. Registration not only enables users to access the AFA, but also use other features on the site.
# # #
Contacts:
George Perry, PhD
Editor-in-Chief, Journal of Alzheimer's Disease
Dean and Professor of Biology, The University of Texas at San Antonio
Tel: +1 210 458 4450
Fax:+1 210 458 4445
E-mail: george.perry@utsa.edu
Daphne Watrin
IOS Press
Tel: +31 20 688 3355
Fax: +31 20 687 0019
E-mail: d.watrin@iospress.nl
NOTES FOR EDITORS
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer's Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment, and psychology of Alzheimer's disease. This peer-reviewed journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease, and clinical trial outcomes. The Journal of Alzheimer's Disease has an Impact Factor of 4.151 according to Thomson Reuters' 2015 Journal Citation Reports®. JAD is published by IOS Press (www.iospress.com).
ABOUT IOS PRESS
Commencing its publishing activities in 1987, IOS Press (www.iospress.nl) serves the information needs of scientific and medical communities worldwide. IOS Press now (co-)publishes over 100 international journals and about 75 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences.
Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008.
